Clinical use in COVID-19
Eculizumab, a humanized anti-C5 monoclonal antibody, is under
investigation as a candidate drug to play a role in the thrombotic
microvascular injury mediated by complement activation causing lung
injury either due to severe pneumonia or ARDS in severe COVID-19
(21,36,168).